These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1251139)

  • 1. Evaluation of prophylactic replacement therapy in haemophilia B.
    Morfini M; Mannucci PM; Mariani G; Panicucci F; Petrucci F; Baicchi U; Capitanio A; Ferrini PL; Mandelli F
    Scand J Haematol; 1976 Jan; 16(1):41-7. PubMed ID: 1251139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prevention of joint damage in hemophilic children with early prophylaxis].
    Kreuz W; Escuriola Ettingshausen C; Funk M; Pons S; Schmidt H; Kornhuber B
    Orthopade; 1999 Apr; 28(4):341-6. PubMed ID: 10335528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The treatment of haemophilia, including prophylaxis, constant infusion and DDAVP.
    Berntorp E
    Baillieres Clin Haematol; 1996 Jun; 9(2):259-71. PubMed ID: 8800504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of investigator-prescribed BeneFIX prophylaxis in children less than 6 years of age with severe haemophilia B.
    Monahan PE; Liesner R; Sullivan ST; Ramirez ME; Kelly P; Roth DA
    Haemophilia; 2010 May; 16(3):460-8. PubMed ID: 20059559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open clinical study assessing the efficacy and safety of Factor IX Grifols, a high-purity Factor IX concentrate, in patients with severe haemophilia B.
    Lissitchkov T; Matysiak M; Zawilska K; Gercheva L; Antonov A; Montañes M; Paez A
    Haemophilia; 2010 Mar; 16(2):240-6. PubMed ID: 20015218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiologic evaluation of prophylaxis in severe haemophilia.
    Pettersson H; Nilsson IM; Hedner U; Noréhn K; Ahlberg A
    Acta Paediatr Scand; 1981 Jul; 70(4):565-70. PubMed ID: 6797235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orthopaedic evaluation in children with severe haemophilia A or B submitted to primary prophylaxis therapy in a coagulopathy treatment centre.
    De Podestá Haje D; Ono F; De Oliveira GB; Almeida J; De Paula JC; Batista Neto LV; Silva Barros SB
    Haemophilia; 2011 Mar; 17(2):228-32. PubMed ID: 21070500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China.
    Wu R; Luke KH; Poon MC; Wu X; Zhang N; Zhao L; Su Y; Zhang J
    Haemophilia; 2011 Jan; 17(1):70-4. PubMed ID: 20579111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study.
    Fischer K; Kulkarni R; Nolan B; Mahlangu J; Rangarajan S; Gambino G; Diao L; Ramirez-Santiago A; Pierce GF; Allen G
    Lancet Haematol; 2017 Feb; 4(2):e75-e82. PubMed ID: 28159192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prevention of severe haemophilia B with a factor IX concentrate (author's transl)].
    Ludwig E; Lechner K
    Dtsch Med Wochenschr; 1974 Jun; 99(25):1355-61. PubMed ID: 4836072
    [No Abstract]   [Full Text] [Related]  

  • 11. Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients.
    Martinowitz U; Lissitchkov T; Lubetsky A; Jotov G; Barazani-Brutman T; Voigt C; Jacobs I; Wuerfel T; Santagostino E
    Haemophilia; 2015 Nov; 21(6):784-90. PubMed ID: 25990590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials.
    Oldenburg J; Carcao M; Lentz SR; Mahlangu J; Mancuso ME; Matsushita T; Négrier C; Clausen WHO; Ehrenforth S; Young G
    Haemophilia; 2018 Nov; 24(6):911-920. PubMed ID: 30248217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B.
    Pasi KJ; Fischer K; Ragni M; Nolan B; Perry DJ; Kulkarni R; Ozelo M; Mahlangu J; Shapiro AD; Baker RI; Bennett CM; Barnes C; Oldenburg J; Matsushita T; Yuan H; Ramirez-Santiago A; Pierce GF; Allen G; Mei B
    Thromb Haemost; 2017 Feb; 117(3):508-518. PubMed ID: 28004057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dental extractions and the use of Christmas factor concentrate in cases of haemophilia B.
    Van Creveld S; Buchner R
    Vox Sang; 1970 May; 18(5):441-9. PubMed ID: 5311512
    [No Abstract]   [Full Text] [Related]  

  • 15. Patterns of tertiary prophylaxis in Canadian adults with severe and moderately severe haemophilia B.
    Jackson SC; Yang M; Minuk L; St-Louis J; Sholzberg M; Card R; Iorio A; Poon MC
    Haemophilia; 2014 May; 20(3):e199-204. PubMed ID: 24589126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor IX concentrate versus prothrombin complex concentrate for the treatment of hemophilia B during surgery.
    Bardin JM; Sultan Y
    Transfusion; 1990 Jun; 30(5):441-3. PubMed ID: 2360238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.
    Valentino LA
    Haemophilia; 2010 Mar; 16(2):263-71. PubMed ID: 20028421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
    Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ;
    Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group.
    White GC; Shapiro AD; Kurczynski EM; Kim HC; Bergman GE
    Thromb Haemost; 1995 May; 73(5):779-84. PubMed ID: 7482403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B.
    Kavakli K; Smith L; Kuliczkowski K; Korth-Bradley J; You CW; Fuiman J; Zupančić-Šalek S; Abdul Karim F; Rendo P
    Haemophilia; 2016 May; 22(3):381-8. PubMed ID: 26823276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.